|
2,143
|
| 17848 |
SERPINE1
|
|
affects_activity of
|
Plasmin
|
|
| 17849 |
PLG
|
|
affects_quantity of
|
Plasmin
|
|
| 17851 |
Amyloid beta peptide (42)
|
|
decreases_activity of
|
Plasmin
|
SDS insoluble Abeta42
|
| 17852 |
Amyloid beta peptide (40)
|
|
decreases_activity of
|
Plasmin
|
SDS insoluble Abeta40
|
|
19604604
|
Alzheimer disease
|
|
6,524
|
| 62775 |
SERPINE1
|
|
decreases_quantity of
|
Plasmin
|
|
|
19056992
|
Diabetes mellitus, type II
Insulin resistance
Polycystic ovary syndrome 1
|
|
8,011
|
| 79226 |
Tissue plasminogen activator
|
|
increases_quantity of
|
Plasmin
|
|
|
2496749
|
Cardiovascular disease
|
|
8,032
|
| 79929 |
Plasmin
|
|
increases_activity of
|
MMP2
|
|
| 79935 |
Plasmin
|
|
increases_activity of
|
MMP9
|
|
|
28397744
|
Chronic kidney disease
|
|
8,411
|
| 85290 |
PLG
|
|
increases_quantity of
|
Plasmin
|
via binding to the the
IGF-II/M6P receptor (=IGF2R)
|
|
26993302
|
Alzheimer disease
Metabolic
|
|
8,414
|
| 85427 |
IGF2R
|
|
increases_quantity of
|
Plasmin
|
via binding Plasminogen (Plg) to M6P/IGFII-R, hereby activating Plg and generating Plm
|
| 85428 |
IGF2R
|
|
interacts (colocalizes) with
|
Plasmin
|
after binding Plasminogen (Plg) to M6P/IGFII-R, hereby generating plasmin (Plm)
|
| 85502 |
Plasmin
|
|
increases_activity of
|
matrix protein catabolic process
|
cited information
|
| 85526 |
Plasmin
|
|
increases_quantity of
|
TGFB1
|
via releasing TGFB1 from LTGFB1 when M6P/IGFII-R is associated with uPA-R (PLAUR)
|
| 85528 |
Plasmin
|
|
decreases_quantity of
|
LTGFB1
|
linked to IGF2R; via releasing TGFB1 from LTGFB1 when M6P/IGFII-R (IGF2R) is associated with uPA-R (PLAUR)
|
| 85533 |
Plasmin
|
|
decreases_quantity of
|
IGF2R
|
via degradation
|
| 85545 |
SERPINF2
|
|
decreases_activity of
|
Plasmin
|
|
|
10092105
|
Metabolic
|
|
8,578
|
| 88491 |
DHCR24
|
|
increases_activity of
|
Plasmin
|
in SH-SY5Y neuroblastoma cells
|
|
18194465
|
Alzheimer disease
Metabolic
|
|
12,080
|
| 118650 |
Plasminogen
|
|
increases_quantity of
|
Plasmin
|
via proteolytic activity of PLAT and PLAU
|
| 118651 |
PLAT
|
|
increases_quantity of
|
Plasmin
|
together with PLAU
|
| 118653 |
PLAU
|
|
increases_quantity of
|
Plasmin
|
together with PLAT
|
| 118655 |
Plasmin
|
|
decreases_quantity of
|
Fibrin clot
|
|
| 126984 |
Plasmin
|
|
decreases_quantity of
|
Fibrin
|
|
|
32348783
|
Cardiovascular disease
COVID-19
|
|
13,349
|
| 125962 |
SERPINE1
|
|
affects_quantity of
|
Plasmin
|
|
| 125966 |
PLAU
|
|
affects_quantity of
|
Plasmin
|
|
| 125967 |
PLAT
|
|
increases_quantity of
|
Plasmin
|
|
| 125968 |
Plasmin
|
|
decreases_activity of
|
extracellular matrix assembly
|
|
| 125970 |
Plasmin
|
|
increases_activity of
|
fibrinolysis
|
|
|
7924884
|
Nephropathy, diabetic
|
|
13,358
|
| 126011 |
Plasmin
|
|
is_part_of
|
SERPINF2-Plasmin complex
|
|
|
33119703
|
COVID-19
|
|
13,359
|
| 126008 |
PLAT
|
|
increases_quantity of
|
Plasmin
|
|
| 126009 |
PLG
|
|
increases_quantity of
|
Plasmin
|
|
|
2966802
|
Hematological
|
|
13,360
|
| 126014 |
PLAU
|
|
increases_quantity of
|
Plasmin
|
|
|
|
Hematological
|
|
13,368
|
| 126028 |
Plasmin
|
|
affects_activity of
|
fibrinolysis
|
|
|
31309890
|
Hematological
|
|
13,380
|
| 126096 |
IGF2R
|
|
increases_quantity of
|
Plasmin
|
|
|
22613725
|
Hematological
|
|
13,383
|
| 126111 |
IGF2R
|
|
increases_quantity of
|
Plasmin
|
in monocytes
|
|
10092105
|
Hematological
|
|
13,537
|
| 127666 |
Plasmin
|
|
increases_quantity of
|
Angiostatin
|
|
|
|
Cardiovascular
|
|
13,538
|
| 127671 |
Angiostatin
|
|
decreases_quantity of
|
Plasmin
|
|
|
19916923
|
Hematological
|
|
13,539
|
| 127699 |
Plasminogen
|
|
increases_quantity of
|
Plasmin
|
through proteolytic activity of PLAT
|
| 127702 |
PLAT
|
|
increases_quantity of
|
Plasmin
|
|
|
28837538
|
Cancer
|
|
15,273
|
| 144410 |
PLAT
|
|
increases_quantity of
|
Plasmin
|
via activating plasminogen
|
| 144411 |
PLG
|
|
increases_quantity of
|
Plasmin
|
when activated by PLAT/tPA
|
| 144412 |
Plasmin
|
|
increases_activity of
|
pro-MMP
|
degrading tight junctions and basal lamina
|
| 144416 |
Plasmin
|
|
increases_activity of
|
ROCK
|
resulting in astrocyte retraction and leading to BBB impairment
|
|
|
Alzheimer disease
|
CIDeRplus